Living after treatment with the Symplicity™ renal denervation system
Since the endovascular procedure does not involve an implant, patients recover quickly and can soon return to their daily living.
Human clinical experience in patients with resistant hypertension suggests that the procedure is safe, straightforward and associated with a substantial and sustained reduction in blood pressure.
Clinical research shows that RDN therapy with the Symplicity™ renal denervationsystem can provide significant and sustained reduction in blood pressure levels for patients with uncontrolled blood pressure despite multiple antihypertensive medication.
The device may usher in a new era in the treatment of hypertension, hopefully allowing a one-time procedure to offer patients a long-lasting benefit.
- Symplicity is a trademark of Medtronic, Inc. and is registered in one or more countries of the world.
Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.
Last updated: 22 Mar 2012
